This observational study explored persistent sexual side effects in 71 otherwise healthy men aged 21–46 who used finasteride for male pattern hair loss. Despite discontinuing the drug, participants reported prolonged issues, with 94% experiencing low libido, 92% reporting erectile dysfunction and decreased arousal, and 69% having difficulty with orgasm. On
This observational study published in the Journal of Sexual Medicine (2012, PMID: 22789024) evaluated 54 otherwise healthy young men who developed persistent sexual side effects after discontinuing finasteride, a 5-alpha-reductase inhibitor used for male pattern baldness. Despite an average of 14 months off the medication, 96% of participants reported ongoing
This 5-year placebo-controlled study investigated the natural progression of androgenetic alopecia (AGA) in men, showing a 26.3% reduction in scalp hair density (loss of 239 hairs) and visible worsening in 75% of participants by year five. The study highlights the consistent and progressive nature of hair loss in untreated individuals,
This 2020 review article from Expert Opinion on Pharmacotherapy (DOI: 10.1080/14656566.2020.1721463, PMID: 32066284) explores the pathogenesis and treatment options for male pattern hair loss (MPHL), or androgenetic alopecia. It highlights that early intervention with finasteride (a 5-alpha-reductase inhibitor) and minoxidil can slow progression and promote partial regrowth, though outcomes are
This 2012 randomized controlled trial published in the Journal of the Medical Association of Thailand (PMID: 23193746) evaluated the efficacy and safety of 3% minoxidil (MNX) versus a combination of 3% minoxidil and 0.1% finasteride (MFX) in 40 men with androgenetic alopecia (AGA) over 24 weeks. The MFX group showed
This 24-month randomized controlled trial (PMID: 12695131) assessed the efficacy and tolerability of finasteride 1 mg daily in 424 men aged 41–60 with mild-to-moderate vertex male pattern hair loss. Finasteride significantly improved hair growth compared to placebo starting at month 6 (p < 0.001) and continued through month 24, as
Finasteride, a 5α-reductase inhibitor, is approved for treating male pattern baldness (androgenetic alopecia) and works by reducing levels of dihydrotestosterone (DHT), a hormone linked to hair loss. Taken orally at 1 mg/day, it significantly improves hair growth and density by preventing the miniaturization of hair follicles. While generally well-tolerated, the
This randomized controlled trial investigated the efficacy and safety of finasteride in Japanese men with androgenetic alopecia (male pattern hair loss). Participants received either 1 mg or 0.2 mg of finasteride or placebo daily for 48 weeks. Results showed significant hair growth improvement in 58% of the 1 mg group
This randomized controlled trial investigated the efficacy of finasteride 1 mg/day in men aged 18 to 41 with androgenetic alopecia over two years. Results showed significant increases in scalp hair counts—107 hairs at 1 year and 138 at 2 years (P < .001)—compared to baseline, while the placebo group experienced
This randomized controlled trial evaluated the efficacy of finasteride 1 mg daily over 24 months in men aged 18 to 60 years with vertex pattern male pattern hair loss. Standardized global photographic assessments showed significant hair regrowth in all scalp regions for younger men (18–41 years), and in the vertex
